About The Leukemia & Lymphoma SocietyThe Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services. Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org . About Curis, Inc. Curis is a drug development company seeking to develop and commercialize next generation targeted small molecule drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and was developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs, including CUDC-427, a small molecule IAP inhibitor, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information, visit Curis' website at www.curis.com. The Curis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11347 Curis Cautionary Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding Curis' expectations regarding the potential safety profile and clinical benefits of CUDC-907, the Company's goals for advancing the molecule through clinical studies and the Company's expectation that LLS will support the Company's subsequent preclinical studies and clinical trials. Forward-looking statements used in this press release may contain the words "believes," "expects," "anticipates," "plans," "seeks," "estimates," "assumes," "will," "may," "could" or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. For example, Curis (i) may not be able to successfully enroll patients in its Phase I clinical trial of CUDC-907, (ii) may experience delays, setbacks and other failures in its planned clinical development of CUDC-907, including negative, inconsistent or inconclusive results, and/or results that fail to achieve the primary or secondary objectives of the trial, (iii) may encounter manufacturing delays or difficulties and (iv) may be required by the FDA or institutional review boards to hold, delay, suspend or terminate such trial. Moreover, Curis may not be able to maintain its collaboration agreement with LLS on terms that are favorable to Curis, or at all. Curis also faces other important risks relating to its business, operations, financial condition and future prospects generally that are discussed in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 and other filings that it periodically makes with the Securities and Exchange Commission. In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis' views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise.
CONTACT: Michael P. Gray Chief Financial and Chief Operating Officer Curis, Inc. 617-503-6632 email@example.com Andrea Greif Director of Public Relations The Leukemia & Lymphoma Society (914) 821-8958 firstname.lastname@example.org